ARTICLE | Finance
Ebb & Flow
June 1, 2009 7:00 AM UTC
On its face, the deal to take out CuraGen Corp. (NASDAQ:CRGN) is returning about $0.18 for every dollar the genomics-based oncology company has raised since it went public. But the $94.5 million all-stock offer announced last Friday by immunotherapeutics company Celldex Therapeutics Inc. (NASDAQ:
CLDX) may turn out to be good deal for current shareholders...